NCT01222078View on ClinicalTrials.gov

Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 22, 2010

Primary Completion Date

May 19, 2011

Study Completion Date

May 19, 2011

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

otelixizumab

Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).

Trial Locations (2)

75877

GSK Investigational Site, Paris

04103

GSK Investigational Site, Leipzig

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01222078 - Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter